564 related articles for article (PubMed ID: 28478033)
1. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
2. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
Goodlett CR; Stringer M; LaCombe J; Patel R; Wallace JM; Roper RJ
Sci Rep; 2020 Jun; 10(1):10426. PubMed ID: 32591597
[TBL] [Abstract][Full Text] [Related]
4. Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
Jamal R; LaCombe J; Patel R; Blackwell M; Thomas JR; Sloan K; Wallace JM; Roper RJ
PLoS One; 2022; 17(2):e0264254. PubMed ID: 35196359
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
Abeysekera I; Thomas J; Georgiadis TM; Berman AG; Hammond MA; Dria KJ; Wallace JM; Roper RJ
Mol Nutr Food Res; 2016 Apr; 60(4):717-726. PubMed ID: 26748562
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
8. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C
Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201
[TBL] [Abstract][Full Text] [Related]
9. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
[TBL] [Abstract][Full Text] [Related]
10. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
Blazek JD; Abeysekera I; Li J; Roper RJ
Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
[TBL] [Abstract][Full Text] [Related]
11. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
[TBL] [Abstract][Full Text] [Related]
12. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
13. Abnormal mineralization of the Ts65Dn Down syndrome mouse appendicular skeleton begins during embryonic development in a Dyrk1a-independent manner.
Blazek JD; Malik AM; Tischbein M; Arbones ML; Moore CS; Roper RJ
Mech Dev; 2015 May; 136():133-42. PubMed ID: 25556111
[TBL] [Abstract][Full Text] [Related]
14. Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup
Gu Y; Moroy G; Paul JL; Rebillat AS; Dierssen M; de la Torre R; Cieuta-Walti C; Dairou J; Janel N
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092951
[TBL] [Abstract][Full Text] [Related]
15. Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome.
Starbuck JM; Llambrich S; Gonzàlez R; Albaigès J; Sarlé A; Wouters J; González A; Sevillano X; Sharpe J; De La Torre R; Dierssen M; Vande Velde G; Martínez-Abadías N
Sci Rep; 2021 Feb; 11(1):4715. PubMed ID: 33633179
[TBL] [Abstract][Full Text] [Related]
16. Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.
Kleschevnikov AM; Yu J; Kim J; Lysenko LV; Zeng Z; Yu YE; Mobley WC
Neurobiol Dis; 2017 Jul; 103():1-10. PubMed ID: 28342823
[TBL] [Abstract][Full Text] [Related]
17. Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome.
Catuara-Solarz S; Espinosa-Carrasco J; Erb I; Langohr K; Gonzalez JR; Notredame C; Dierssen M
eNeuro; 2016; 3(5):. PubMed ID: 27844057
[TBL] [Abstract][Full Text] [Related]
18. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
[TBL] [Abstract][Full Text] [Related]
19. Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models.
Souchet B; Duchon A; Gu Y; Dairou J; Chevalier C; Daubigney F; Nalesso V; Créau N; Yu Y; Janel N; Herault Y; Delabar JM
Sci Rep; 2019 Mar; 9(1):3914. PubMed ID: 30850713
[TBL] [Abstract][Full Text] [Related]
20. Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
Yin X; Jin N; Shi J; Zhang Y; Wu Y; Gong CX; Iqbal K; Liu F
Sci Rep; 2017 Apr; 7(1):619. PubMed ID: 28377597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]